Randomized phase II study of proteinase 3-derived PR1 vaccine and GM-CSF with or without peg-interferon alfa-2b to eradicate minimal residual disease in chronic myeloid leukemia

Journal article

Peer reviewed

A. Quintas-Cardama, H. M. Kantarjian, E. Wieder, J. Molldrem and J. E. Cortes

Journal of clinical oncology, Vol.26(15_suppl), pp.22043-22043

2008-05-20

Metrics

2 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.1126 Chronic Myeloid Leukemia
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Randomized phase II study of proteinase 3-derived PR1 vaccine and GM-CSF with or without peg-interferon alfa-2b to eradicate minimal residual disease in chronic myeloid leukemia
Creators: A. Quintas-Cardama
H. M. Kantarjian
E. Wieder
J. Molldrem
J. E. Cortes
Publication Details: Journal of clinical oncology, Vol.26(15_suppl), pp.22043-22043
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031740162302976